^
    5d
    Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    oxaliplatin • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • fluorouracil topical • quemliclustat (AB680)
    7d
    Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Roswell Park Cancer Institute | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    14d
    Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo (clinicaltrials.gov)
    P4, N=60, Recruiting, Al-Azhar University | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    fluorouracil topical
    29d
    ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov)
    P3, N=712, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Dec 2026 | Trial primary completion date: Jan 2028 --> Feb 2025
    Trial completion date • Trial primary completion date • Mismatch repair • Tumor mutational burden
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CD4 (CD4 Molecule)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
    30d
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Recruiting, Mayo Clinic | Trial completion date: Jan 2026 --> Apr 2030 | Trial primary completion date: Jan 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    30d
    NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, OHSU Knight Cancer Institute | N=60 --> 42
    Enrollment change
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    1m
    Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Mazandaran University of Medical Sciences | Not yet recruiting --> Recruiting | Trial completion date: Oct 2025 --> Aug 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    fluorouracil topical
    1m
    Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=128, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel • docetaxel • fluorouracil topical
    1m
    Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov)
    P3, N=129, Not yet recruiting, City of Hope Medical Center
    New P3 trial
    |
    Avastin (bevacizumab) • irinotecan • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    2ms
    A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov)
    P1, N=25, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    2ms
    NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Oct 2025 --> Jan 2027 | Trial primary completion date: Apr 2025 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical